Physician-supervised peptide protocols have become one of the more significant practice-builders for med spas over the last three years. Done correctly, they extend average patient lifetime value, differentiate your practice from competitors, and create a recurring revenue base that aesthetic-only services can't match. Done incorrectly, they create regulatory exposure that can shut down a practice.
This guide walks through what you actually need to set up peptide therapy responsibly in a med spa environment in 2026.
Step 1: Get Your Legal and Medical Supervision Structure Right
Peptide therapy in a med spa environment requires physician oversight. This is non-negotiable in every US state. The specific supervision requirements vary — some states require a physician on-site, others allow telehealth-based medical director oversight for certain services — but the underlying principle is constant: a licensed physician must be directing the clinical protocols.
Medical Director vs. Independent Physician Practice
Most med spas operate under a medical director model: a licensed physician (MD or DO) serves as the medical director, provides protocols, reviews patient charts, and provides the legal foundation for clinical services. The medical director may not see patients directly; their role is supervisory and protocol-based.
For peptide therapy specifically, the medical director should be issuing protocols for each peptide offered, setting dosing parameters and contraindication criteria, and maintaining visibility into which patients are receiving which protocols.
Telehealth-Based Oversight
For med spas without a physician on-site, telehealth-based medical directors have become a practical solution. The patient consult, intake, and protocol selection happen via telemedicine; the med spa staff administer under a standing order framework. Legal requirements vary by state, so consult with a healthcare attorney before implementing.
Step 2: Understand What You Can and Cannot Say
This is where most med spas make costly compliance mistakes. Peptides distributed for physician-supervised clinical research protocols cannot be marketed as drugs or treatments. You cannot state or imply that a peptide treats, cures, or prevents any condition.
What this means practically:
Compliant Language
'BPC-157 is a research-grade peptide used in physician-supervised protocols for gut and joint support research.' 'Sermorelin is a growth hormone releasing hormone analogue used in physician-supervised protocols for longevity and body composition research.'
Non-Compliant Language
'BPC-157 heals leaky gut.' 'Sermorelin reverses aging.' 'This peptide will reduce your inflammation.' Any language that assigns a therapeutic outcome to a specific peptide as a definitive statement is non-compliant.
The distinction matters legally and practically. Train every staff member who discusses peptides with patients on this distinction. It should be in your employee handbook and your patient communication templates.
Step 3: Source From a Compliant Distributor
The quality and sourcing of your peptides is not just a clinical issue — it is a compliance and liability issue. Research-grade peptides distributed for physician-supervised protocols must come from registered, documented supply chains.
What to Look for in a Peptide Distributor
Certificate of Analysis (COA) for every batch, including purity testing, sterility testing, and endotoxin testing. A registered and documented supply chain. Clear communication about the research-grade classification. A documented process for handling lot recalls or quality issues. Willingness to provide documentation that supports your clinical records.
Avoid any distributor who cannot provide batch-level documentation, who makes therapeutic efficacy claims in their marketing, or who distributes to unlicensed individuals.
Step 4: Design Your Protocol Suite
A well-structured med spa peptide menu typically includes two to four core protocols rather than a long catalog. Depth and execution quality matter more than breadth.
High-Demand Starting Protocols for Med Spas
Weight loss and body composition protocols using GLP-1 peptides (semaglutide, tirzepatide) are the highest-demand category currently. Note that GLP-1 compounding rules are shifting; confirm the current regulatory status with your distributor before offering.
Anti-aging and longevity protocols using growth hormone secretagogues (sermorelin, CJC-1295, ipamorelin) are consistently strong performers in med spa environments where the patient population skews health-optimization-oriented.
Gut and tissue support protocols using BPC-157 should now be characterized exclusively as physician-supervised research protocols given the April 2026 FDA Category 2 removal. Review your medical director's protocol framework for this category specifically.
Step 5: Patient Intake and Consent
Every patient entering a peptide protocol should complete a dedicated intake form addressing current medications, relevant health history, and contraindications specific to the peptide category. Signed informed consent should explicitly describe the research-grade nature of the protocol, the absence of FDA approval for these specific uses, and the physician supervision structure.
These documents are not formalities — they are your compliance foundation. A well-documented patient file is your protection in the event of any regulatory inquiry or adverse event.
Step 6: Staff Training
The person administering subcutaneous injections must be licensed to do so in your state. In most states, this means a licensed nurse (RN or LPN) or a medical assistant under direct physician supervision. Know your state's scope-of-practice laws before designating who can administer.
Beyond licensure, every patient-facing staff member should be trained on compliant communication about peptides, on your informed consent process, and on how to escalate patient questions that require physician involvement.
The Business Case
A med spa with 100 active peptide patients at an average monthly protocol cost of $350–$600 is generating $35,000–$60,000 per month in additional revenue. The protocols are highly retentive — patients who are seeing outcomes stay on protocol — and they drive ancillary service utilization as health-focused patients engage more deeply with the broader practice menu.
The investment to stand up a peptide program — medical director time, protocol development, staff training, and sourcing relationships — is typically recovered within 60–90 days for a practice with an existing patient base to sell into.